New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes.

New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. Curr Opin Immunol. 2013 May 29; Authors: Bunting KL, Melnick AM Abstract The BCL6 oncogenic repressor is a master regulator of humoral immunity and B-cell lymphoma survival. Whereas much research has focused on its regulation and function in germinal center B-cells, its role in other mature lymphoid cell compartments is less clear. A novel role for BCL6 in follicular T helper cell development was recently uncovered. The latest discoveries reveal that BCL6 is also an important regulator of other specialized helper T-cell subsets within germinal centers, pre-germinal center events, and peripheral T-cell effector functions. Here, we review newly discovered roles for BCL6 in lymphocyte subsets residing within and outside of germinal centers, and discuss their implications with respect to the molecular mechanisms of BCL6 regulation and potential links to B and T-cell lymphomas. PMID: 23725655 [PubMed - as supplied by publisher]
Source: Current Opinion in Immunology - Category: Allergy & Immunology Authors: Tags: Curr Opin Immunol Source Type: research

Related Links:

Condition:   Extranodal NK/T-cell Lymphoma Interventions:   Drug: Sintilimab;   Drug: Decitabine Sponsor:   Beijing Tongren Hospital Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Abstract: Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL-NT), is a rare subtype of non-Hodgkin lymphoma associated with Epstein–Barr virus. This type of lymphoma is rare in Western countries but is more frequent in East Asia and Latin America. ENKTL-NT mostly occurs in the nose and paranasal area, including the upper aerodigestive tract. The skin is the second-most commonly involved organ. ENKTL-ET is characterized by an angiocentric, angiodestructive pattern of growth with ulceration and necrosis evident on histopathological examination. We provide the first description of ENKTL-NT presenting with in...
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Brief Report Source Type: research
We report on a 74-year-old man with a cutaneous B-cell follicle center lymphoma, which was treated upfront with systemic rituximab and suffered several local relapses. The first of the local recurrences, 10 months after completion of treatment, was characterized by a dense T-cell infiltrate that obscured a minor population of B-cell lymphoma cells, suggesting a second primary cutaneous T-cell lymphoma. This represents a previously not reported diagnostic pitfall and underscores the importance of performing sequential biopsies when dealing with lymphoma recurrences in this setting.
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Extraordinary Case Report Source Type: research
Abstract Marek's disease virus (MDV) is a highly oncogenic alphaherpesvirus that causes deadly T-cell lymphomas and serves as a natural virus-induced tumor model in chickens. Although Marek's disease (MD) is well controlled by current vaccines, the evolution of MDV field viruses towards increasing virulence is concerning as a better vaccine to combat very virulent plus MDV is still lacking. Our understanding of molecular and cellular immunity to MDV and its immunopathogenesis has significantly improved, but those findings about cellular immunity to MDV are largely out-of-date, hampering the development of more eff...
Source: Cellular and Molecular Life Sciences : CMLS - Category: Cytology Authors: Tags: Cell Mol Life Sci Source Type: research
AbstractLymphomas are a large, heterogeneous group of neoplasms with well-defined characteristics, and this heterogeneity highlights the importance of epidemiological data. Knowledge of local epidemiology is essential to optimise resources, design clinical trials, and identify minority entities. Given there are few published epidemiological data on lymphoma in Spain, the Spanish Lymphoma and Autologous Bone Marrow Transplant Group created the RELINF project. The aim of this project is to determine the frequencies and distribution of lymphoid neoplasms in Spain and to analyse survival. We developed an online platform for th...
Source: Annals of Hematology - Category: Hematology Source Type: research
To the Editor: Mechlorethamine (ie, nitrogen mustard) is a skin-directed therapy (SDT) for mycosis fungoides-cutaneous T-cell lymphoma (MF-CTCL) used since the mid-1900s, with response rates of 70% to 80%.1-3 Mechlorethamine gel (MG) 0.016% (Valchlor; Helsinn Therapeutics, Iselin, NJ) was United States Food and Drug Administration approved in 2013 (stages IA/IB). PROVe (A PROspective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor ®, identifier: N...
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Tags: Letter Source Type: research
Primary Cutaneous Gamma-Delta (γδ) T-Cell Lymphoma (PCGDTCL) is a rare primary cutaneous lymphoma of aggressive nature. Only a few cases with an initially indolent course over years have been published. PCGDTCL can mimic diseases with benign behavior in their clinical and histopathological presentation, such as lupus erythematosus profundus, but also other lymphomas, for example subcutaneous panniculitis-like T-cell lymphoma. In our patient, the results of histopathological, immunofluorescence microscopy, and clinical examinations of early lesions first led to the diagnosis of lupus erythematosus profundus. Two...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
, Brenner W, Giagounidis A, Moeller R, Runde V, Sandmann M, Hautzel H, Wilop S, Krohn T, Dürk H, Heike M, Alashkar F, Brinkmann M, Trenn G, Wacker D, Kreisel-Büstgens C, Bernhard H, Heil G, Larisch R, Kurch L, Jöckel KH, Hoelzer D, Klapper W, Boellaard R, Dührsen U, Hüttmann A Abstract The prospective randomized Positron Emission Tomography (PET)-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) trial was designed to test the ability of interim PET (iPET) to direct therapy. As reported previously, outcome remained unaffected by iPET-based treatment changes. In this subgroup analys...
Source: Hamostaseologie - Category: Hematology Authors: Tags: Hematol Oncol Source Type: research
Leukemia, Published online: 17 February 2020; doi:10.1038/s41375-020-0740-1A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group
Source: Leukemia - Category: Hematology Authors: Source Type: research
In this study, we designed a new prognostic model specifically for ENKTL to improve the risk stratification. In 29 ENKTL patients, we screened mutations in 9 ENKTL-associated genes using next-generation sequencing (NGS). We have found that mutated KMT2D was associated with the inferior overall survival (OS) and progression free survival (PFS) and KMT2D or TP53 mutations were associated with higher mortality rate. Moreover, the difference in PFS among different stratifications was not significant using the International Prognostic Index (IPI) alone, but was significant after the mutation status of KMT2D and TP53 were incorp...
Source: Neoplasma - Category: Cancer & Oncology Authors: Tags: Neoplasma Source Type: research
More News: Allergy & Immunology | Cancer & Oncology | Lymphoma | T-cell Lymphoma